Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study
- VernacularTitle:初诊慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗现状分析：国内多中心、回顾性真实世界研究
- Author:
Xiaoshuai ZHANG
1
;
Bingcheng LIU
;
Xin DU
;
Yanli ZHANG
;
Na XU
;
Xiaoli LIU
;
Weiming LI
;
Hai LIN
;
Rong LIANG
;
Chunyan CHEN
;
Jian HUANG
;
Yunfan YANG
;
Huanling ZHU
;
Ling PAN
;
Xiaodong WANG
;
Guohui LI
;
Zhuogang LIU
;
Yanqing ZHANG
;
Zhenfang LIU
;
Jianda HU
;
Chunshui LIU
;
Fei LI
;
Wei YANG
;
Li MENG
;
Yanqiu HAN
;
Li'e LIN
;
Zhenyu ZHAO
;
Chuanqing TU
;
Caifeng ZHENG
;
Yanliang BAI
;
Zeping ZHOU
;
Suning CHEN
;
Huiying QIU
;
Lijie YANG
;
Xiuli SUN
;
Hui SUN
;
Li ZHOU
;
Zelin LIU
;
Danyu WANG
;
Jianxin GUO
;
Liping PANG
;
Qingshu ZENG
;
Xiaohui SUO
;
Weihua ZHANG
;
Yuanjun ZHENG
;
Qian JIANG
Author Information
- Keywords: Leukemia, myeloid, chronic; Tyrosine kinase inhibitor; Treatment status; Multi-centre; Real-world study
- From: Chinese Journal of Hematology 2024;45(3):215-224
- CountryChina
- Language:Chinese
- Abstract: Objective:To retrospectively analyze the treatment status of tyrosine kinase inhibitors (TKI) in newly diagnosed patients with chronic myeloid leukemia (CML) in China.Methods:Data of chronic phase (CP) and accelerated phase (AP) CML patients diagnosed from January 2006 to December 2022 from 77 centers, ≥18 years old, and receiving initial imatinib, nilotinib, dasatinib or flumatinib-therapy within 6 months after diagnosis in China with complete data were retrospectively interrogated. The choice of initial TKI, current TKI medications, treatment switch and reasons, treatment responses and outcomes as well as the variables associated with them were analyzed.Results:6 893 patients in CP ( n=6 453, 93.6%) or AP ( n=440, 6.4%) receiving initial imatinib ( n=4 906, 71.2%), nilotinib ( n=1 157, 16.8%), dasatinib ( n=298, 4.3%) or flumatinib ( n=532, 7.2%) -therapy. With the median follow-up of 43 ( IQR 22-75) months, 1 581 (22.9%) patients switched TKI due to resistance ( n=1 055, 15.3%), intolerance ( n=248, 3.6%), pursuit of better efficacy ( n=168, 2.4%), economic or other reasons ( n=110, 1.6%). The frequency of switching TKI in AP patients was significantly-higher than that in CP patients (44.1% vs 21.5%, P<0.001), and more AP patients switched TKI due to resistance than CP patients (75.3% vs 66.1%, P=0.011). Multi-variable analyses showed that male, lower HGB concentration and ELTS intermediate/high-risk cohort were associated with lower cytogenetic and molecular responses rate and poor outcomes in CP patients; higher WBC count and initial the second-generation TKI treatment, the higher response rates; Ph + ACA at diagnosis, poor PFS. However, Sokal intermediate/high-risk cohort was only significantly-associated with lower CCyR and MMR rates and the poor PFS. Lower HGB concentration and larger spleen size were significantly-associated with the lower cytogenetic and molecular response rates in AP patients; initial the second-generation TKI treatment, the higher treatment response rates; lower PLT count, higher blasts and Ph + ACA, poorer TFS; Ph + ACA, poorer OS. Conclusion:At present, the vast majority of newly-diagnosed CML-CP or AP patients could benefit from TKI treatment in the long term with the good treatment responses and survival outcomes.
